Sonova stock holds after fiscal 2025 sales and profit growth

Sonova Holding AG (CH0012549785) is supported by fiscal 2025 revenue of CHF 3.87 billion and core EBITA of CHF 807.4 million, while the Swiss hearing-care group reported 7.6% sales growth and 6.5% organic growth for the year ended 31 March 2025. Sonova stock also closed the year with a reported net profit of CHF 547.2 million, underscoring that the latest published annual figures still set the tone for valuation, margins, and cash generation.

Revenue up 7.6%

In the year ended 31 March 2025, Sonova reported group sales of CHF 3.87 billion, up 7.6% in reported terms and 6.5% organically. That comparison matters because it shows that the company expanded both on a nominal basis and after stripping out currency and acquisition effects.

The same annual report also put core EBITA at CHF 807.4 million, which leaves the group with a core EBITA margin of 20.9% on the reported sales base. Net profit reached CHF 547.2 million for fiscal 2025, giving investors a second profitability marker alongside operating earnings.

Profit and margin mix

The margin profile is the key question after a year like this. A CHF 807.4 million core EBITA result on CHF 3.87 billion of sales suggests that Sonova kept a high operating spread even while continuing to grow revenue at mid-single-digit rates in organic terms.

The annual profit figure of CHF 547.2 million adds another layer to the picture because it shows how operating performance flowed through to the bottom line in fiscal 2025. For a hearing-aid manufacturer, that combination of growth and profitability usually matters more than one isolated quarterly beat.

Hearing aids drive the group

Sonova's core business is hearing solutions, including hearing aids and related services, and that product base is what converts the annual numbers into a longer-term market case. The latest annual figures show that this portfolio still generated CHF 3.87 billion in sales in fiscal 2025, which remains the central reference point for the stock.

For investors, the product mix matters because the hearing-aid category is where the company converts replacement demand, new fittings, and service revenue into recurring sales. The 31 March 2025 year-end figures show that Sonova entered the new financial year with a larger revenue base and a double-digit operating margin profile at the core EBITA level.

Stock level and market view

Sonova stock can be read through those fiscal 2025 numbers until the market posts a new dated quote or a new company release becomes available. In the current article context, the important anchor is not a day-trading swing but the combination of CHF 3.87 billion in sales, CHF 807.4 million in core EBITA, and CHF 547.2 million in net profit for the year ended 31 March 2025.

That set of figures gives the Swiss group a clear earnings base, and the 7.6% reported sales growth is the most direct year-over-year comparison in the latest annual data. The stock case therefore rests on whether Sonova can keep converting that sales momentum into a similar operating margin in the next reporting cycle.

Hearing solutions portfolio

Hearing aids remain the central commercial product line for Sonova, and the annual report framework shows why that category matters. With CHF 3.87 billion in fiscal 2025 revenue and CHF 807.4 million in core EBITA, the hearing-solutions portfolio remains the main engine behind the group outcome.

Sonova stock closing view

Sonova stock is anchored here by the latest annual report figures rather than a fresh quote. The company reported CHF 3.87 billion in sales, CHF 807.4 million in core EBITA, and CHF 547.2 million in net profit for fiscal 2025, all for the year ended 31 March 2025.